Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flow from operating activities
Net income (loss)	$ 101,836	$ (40,406)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation expense	5,230	4,809
Depreciation	2,161	4,016
Amortization of premiums and discounts on marketable securities	(25)	2
Loss on disposal of fixed assets	124
Other non-cash items		(2,469)
Changes in operating assets and liabilities:
Related party collaboration receivable	(3,093)	581
Prepaid expenses and other current assets	(686)	6
Operating lease, right-of-use asset	957	2,556
Accounts payable	(907)	644
Accrued expenses	1,296	(3,652)
Operating lease liabilities	(1,385)	(2,647)
Other non-current liabilities		(287)
Deferred revenue	17,222	52,787
Net cash provided by operating activities	122,730	15,941
Cash flow from investing activities
Purchases of property and equipment	(1,719)	(1,280)
Purchases of marketable securities	(28,453)	(54,848)
Proceeds from sales and maturities of marketable securities	20,000
Net cash provided by investing activities	(10,172)	(56,128)
Cash flow from financing activities
Proceeds from the exercise of stock options	1,414	587
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	31,121
Proceeds from the purchase of common stock under ESPP	319	232
Net cash provided by financing activities	32,854	819
Net increase (decrease) in cash, cash equivalents, and restricted cash	145,412	(39,368)
Cash, cash equivalents, and restricted cash beginning of period	100,474	119,212
Cash, cash equivalents, and restricted cash end of period	245,886	79,844
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid	$ 52	$ 113